Maternal Systemic Lupus Erythematosus: Neonatal Lupus and Heart Block

Maternal systemic lupus erythematosus (SLE) can affect pregnancy through disease activity, organ involvement, medications, placental dysfunction, and the transfer of maternal autoantibodies across the placenta. Most pregnancies are successful when conception occurs during a stable period and care is coordinated between rheumatology, maternal-fetal medicine, obstetrics, and neonatology.

Neonatal lupus is an antibody-mediated condition in the fetus or newborn. It is associated mainly with maternal anti-Ro/SSA and anti-La/SSB antibodies, which may be present in women with SLE, Sjögren syndrome, undifferentiated connective tissue disease, or no diagnosed autoimmune illness. The most serious manifestation is fetal atrioventricular conduction disease, commonly called congenital heart block.

The subject belongs within the wider field of perinatal and neonatal medicine represented by the FAOPS 2020 congress archive, which brought together research and clinical perspectives from Asian and Oceanian perinatal societies. Although the planned Tokyo meeting was canceled during the COVID-19 pandemic, the clinical questions surrounding autoimmune pregnancy remain highly relevant.

How Maternal Autoantibodies Affect the Fetus

Anti-Ro/SSA and anti-La/SSB antibodies are immunoglobulin G antibodies. Because IgG crosses the placenta, these antibodies can reach the fetal circulation, particularly during the second trimester when transplacental transfer becomes increasingly active. They may bind to proteins in fetal tissues and trigger inflammation, complement activation, and subsequent scarring.

The term neonatal lupus can be misleading because the infant does not usually have childhood-onset SLE. The condition results from passively acquired maternal antibodies, and symptoms generally improve as those antibodies are cleared from the infant’s circulation. A newborn may develop a characteristic annular or photosensitive rash, low platelet or white blood cell counts, elevated liver enzymes, or cardiac involvement.

The presence of anti-Ro or anti-La antibodies does not mean that fetal complications will occur. Most exposed infants do not develop complete heart block. Risk is higher when the mother has previously had a child affected by neonatal lupus or congenital heart block, although a first affected pregnancy can occur without warning and without severe maternal disease.

Why Congenital Heart Block Is the Major Concern

The fetal cardiac conduction system can be injured when antibody-associated inflammation affects the atrioventricular node and nearby tissue. The process may begin with a prolonged PR interval, progress to second-degree block, and then become complete or third-degree heart block. Complete block is generally permanent because fibrosis replaces damaged conduction tissue.

Fetal heart block is often detected between 18 and 24 weeks of gestation, but surveillance windows vary according to antibody status, prior pregnancy history, local protocols, and available expertise. A fetal echocardiogram can assess atrioventricular conduction, rhythm, ventricular function, valvular regurgitation, and signs of myocarditis or cardiomyopathy.

Heart block may occur in a fetus whose mother has no symptoms of active lupus. Conversely, active maternal disease does not automatically produce fetal conduction disease. This distinction matters during counseling: maternal clinical stability is essential for pregnancy health, but antibody-related cardiac risk requires its own assessment and monitoring strategy.

Planning Pregnancy With Lupus and Anti-Ro Antibodies

Preconception care should establish whether SLE is clinically and serologically stable. Physicians commonly review kidney function, urine protein, blood pressure, complement levels, anti-double-stranded DNA antibodies, blood counts, antiphospholipid antibodies, and current medications. Active nephritis, uncontrolled hypertension, pulmonary hypertension, or significant cardiac disease may make pregnancy unsafe until treatment is optimized.

Medication planning should occur before conception rather than after a positive pregnancy test. Hydroxychloroquine is commonly continued during pregnancy when medically appropriate and is an important part of lupus control. Stopping effective therapy can increase the risk of a maternal flare. Other medicines, including mycophenolate, methotrexate, and cyclophosphamide, require specialist review because of fetal risks and the need for safe alternatives.

Women known to carry anti-Ro/SSA or anti-La/SSB antibodies should receive individualized counseling. A previous child with congenital heart block substantially changes recurrence counseling, with commonly cited recurrence estimates near 15–20%, compared with a much lower risk in antibody-positive women without such a history. The exact estimate varies by study and clinical context.

Monitoring Fetal Rhythm and Cardiac Function

Serial fetal echocardiography is often considered from approximately 16–18 weeks through 26 weeks for antibody-positive pregnancies, when the risk of developing conduction abnormalities is most clinically important. Some centers use weekly examinations for higher-risk pregnancies, while others combine formal echocardiography with frequent fetal heart-rate assessment and maternal reporting of symptoms or concerns.

No monitoring schedule eliminates risk. Heart block can develop between examinations, and the ideal frequency remains an area of clinical discussion. Fetal echocardiography should be performed by clinicians experienced in assessing rhythm and conduction, with a clear plan for urgent review if a prolonged PR interval, bradycardia, ventricular dysfunction, or hydrops appears.

Treatment for evolving conduction disease remains complex. Fluorinated corticosteroids such as dexamethasone may be considered in selected cases, particularly when inflammation or incomplete block is suspected, but evidence is mixed and treatment can carry maternal and fetal adverse effects. Established complete heart block usually does not reverse with steroids. Intravenous immunoglobulin, plasmapheresis, and other therapies have been studied, yet they are not routine solutions and should be considered only by an experienced specialist team.

Preparing for Delivery and Newborn Assessment

Delivery timing and route should be based on obstetric indications, fetal growth, cardiac function, rhythm, and the resources available at the birth facility. Congenital heart block alone does not always require preterm delivery or cesarean birth. A planned birth at a center with neonatal intensive care, pediatric cardiology, and pacing capability may be appropriate when the fetal ventricular rate is very slow or cardiac function is impaired.

At birth, the newborn should receive a careful cardiovascular examination, pulse assessment, electrocardiogram, and usually echocardiography if exposure to anti-Ro or anti-La antibodies occurred. Monitoring can identify bradycardia, prolonged conduction intervals, ventricular dysfunction, structural abnormalities, or pulmonary complications. A pacemaker may be required when the heart rate is inadequate for cardiac output or the infant develops symptoms.

Noncardiac neonatal lupus findings are often temporary. Skin lesions may be triggered or worsened by ultraviolet exposure and can appear weeks after birth. Parents should receive practical advice about sun protection and follow-up. Cytopenias and liver abnormalities generally resolve as maternal antibodies disappear, but significant abnormalities require pediatric evaluation and serial laboratory testing.

Cardiac follow-up remains important even when the newborn appears well. A normal examination immediately after birth does not replace an electrocardiogram or specialist review. Infants with any rhythm abnormality need individualized surveillance, while those with complete block require long-term cardiology care even if they remain clinically stable.

Counseling Families About Risk and Uncertainty

Risk communication should avoid implying that antibody positivity predicts a poor pregnancy. The majority of antibody-exposed pregnancies do not result in congenital heart block, and neonatal lupus skin, liver, or blood findings are also uncommon. At the same time, the potential severity of cardiac disease justifies organized surveillance and rapid escalation when abnormalities appear.

Families should understand the difference between prevention and treatment. Maintaining lupus remission, continuing appropriate medication, and using hydroxychloroquine when indicated may reduce risk, but no strategy guarantees prevention. Once complete heart block is established, management usually focuses on fetal well-being, ventricular performance, delivery planning, and newborn pacing rather than expecting restoration of normal conduction.

Care is strongest when communication is explicit. The obstetric team should know the antibody profile and previous pregnancy history; the fetal cardiologist should communicate what findings require urgent action; and the neonatal team should be involved before birth when a slow fetal rate or structural concern is present. Broader lessons about coordinated care and preparedness are also reflected in discussions of resilient perinatal systems, especially when specialist access or travel is disrupted.

Practical Priorities for Clinical Care

• Confirm anti-Ro/SSA and anti-La/SSB status before or early in pregnancy when SLE or another autoimmune condition is present.
• Aim for stable maternal disease before conception and review every medication with a rheumatology and maternal-fetal medicine team.
• Arrange a fetal surveillance plan that reflects antibody status, gestational age, local expertise, and any history of neonatal lupus or heart block.
• Escalate promptly when fetal bradycardia, conduction delay, ventricular dysfunction, hydrops, or an abnormal fetal echocardiogram is detected.
• Plan newborn electrocardiography, cardiac assessment, laboratory review, and pediatric follow-up before delivery.

Maternal SLE with anti-Ro/SSA or anti-La/SSB antibodies calls for vigilance rather than alarm. Early counseling, appropriate medication, structured fetal monitoring, and coordinated neonatal planning can help clinicians identify conduction disease quickly and prepare families for the care that may follow. Use this topic as a starting point for multidisciplinary protocols, patient education, and continued perinatal research.